quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:08·434d
SECFiling
Marinus Pharmaceuticals Inc. logo

SEC Form EFFECT filed by Marinus Pharmaceuticals Inc.

MRNS· Marinus Pharmaceuticals Inc.
Health Care
Original source

Companies

  • MRNS
    Marinus Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Sep 23UpdateOppenheimer$6.00
  • Aug 14UpdateLadenburg Thalmann-
  • Apr 16UpdateRobert W. Baird$2.00
  • Apr 15UpdateRBC Capital Mkts$3.00
  • Aug 11UpdateOppenheimer$9.00
  • Jan 20UpdateRBC Capital Mkts$23.00

Related

  • SEC426d
    SEC Form 15-12G filed by Marinus Pharmaceuticals Inc.
  • SEC433d
    Amendment: SEC Form SCHEDULE 13G/A filed by Marinus Pharmaceuticals Inc.
  • SEC434d
    SEC Form EFFECT filed by Marinus Pharmaceuticals Inc.
  • SEC434d
    SEC Form EFFECT filed by Marinus Pharmaceuticals Inc.
  • SEC436d
    Amendment: SEC Form SCHEDULE 13G/A filed by Marinus Pharmaceuticals Inc.
  • INSIDER436d
    Director Ezickson Elan returned $5,995 worth of shares to the company (10,900 units at $0.55), closing all direct ownership in the company (SEC Form 4)
  • INSIDER436d
    Director Fischer Seth H. Z. returned $8,254 worth of shares to the company (15,007 units at $0.55), closing all direct ownership in the company (SEC Form 4)
  • INSIDER436d
    CHIEF MEDICAL OFFICER Hulihan Joseph returned $39,999 worth of shares to the company (72,725 units at $0.55), closing all direct ownership in the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022